Despite advances in chemotherapy and immunotherapy, advanced lung cancer remains an
incurable disease. Novel trends in anticancer therapeutics focus on harnessing the …

Excision tissue biopsy, while central to cancer treatment and precision medicine, presents
risks to the patient and does not provide a sufficiently broad and faithful representation of the …

Though Dehydrocorydaline, an alkaloid isolated from Corydalis turtschaninovii tuber, was
known to have anti‐coronary artery disease, anti‐inflammatory, apoptotic, anti‐allergic, anti …

Recent studies have demonstrated that exon 19 deletion (19 Del) and exon 21 L858R
mutation (L858R) are 2 different types of sensitive epidermal growth factor receptor (EGFR) …

Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other
commonly used drugs in different treatment settings and epidermal growth factor receptor …

Recent developments in personalized medicine are based on molecular measurement
steps that guide personally adjusted medical decisions. A central approach to molecular …

Previous studies have indicated that lung adenocarcinoma (LUAD) is one of the common
human malignancies, and its incidence keeps rising. With the help of microarray technology …

Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …

Abstract Activating transcription factor 2 (ATF2) is a member of the cAMP response element
binding protein family that heterodimerizes and activates other transcription factors involved …

The breakthrough of programmed cell death protein 1 (PD‐1) blockade therapy has
changed the clinical treatment of non‐small cell lung cancer (NSCLC) in the past few years …